Coverage Initiated: April 2003
Coverage Terminated: August 2011

SciClone (SCLN) strategy is to develop and commercialize therapeutics targeting indications representing significant market needs, especially in oncology and infectious diseases. For now, SciClone’s main story is as an international company, especially in China. Its increasing profits derive from developing a vertically integrated Chinese pharmaceutical presence. It is also trying to develop the European Market for sales.

 Zadaxin flunked yet another trial for treating HCV, but SciClone relies on its China revenues and it expanding Zadaxin’s reach into Europe as a vaccine immune enhancer.

SCV-07 is designed for the treatment of oral mucositis. We have a somewhat dimmer view regarding SCV-07 as an interferon sparing agent for treating HCV.

We terminated coverage of SciClone as the company has decided to sit on its hands insteasd of aggressively developing new drugs. Questions about the accuracy of overseas earnings and a US Justice Department inquiry into possible bribery of foreign officials also raise concerns.

A complete listing of our research on SciClone is available by clicking here.